AstraZeneca shows cardiovascular safety for roxadustat

pharmaphorum | May 10, 2019

AstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm the drug’s cardiovascular safety – a good sign for the potential blockbuster that hopes to compete with well-established treatments. Roxadustat, co-developed with FibroGen and Astellas, is a first-in-class HIF-PHI inhibitor for the treatment of anaemia caused by chronic kidney disease (CKD), which affects more than 200 million people worldwide. It is looking to take on a market well-served for decades by erythropoiesis stimulating agents (ESAs). These drugs suffer from safety concerns, including greater risks of cardiovascular events and tumours, giving AstraZeneca a good reason to be shouting about the positive safety analysis for roxadustat.

Spotlight

Learn about the industry’s first pharmaceutical supply chain solution that is reducing the cost of care and ensuring access to critical medications for hospitals and health systems.


Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More